Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition...
Staff
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules...
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under...
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies...
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy --...
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18...
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Poster presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant...
PreveCeutical’s Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX:...
New Report on Tackling Plastic Waste Highlights SC Johnson for Achieving Key Packaging Goals Early
SC Johnson Leads Industry in Reuse Models in the Ellen MacArthur Foundation's latest Global Commitment Progress ReportRacine, Wisconsin--(Newsfile Corp. -...
Therma Bright to Spin Off Consumer Product Portfolio to Create Two Publicly Traded Companies
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment...
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Buyback of Class B shares in Essity during week 46, 2024
STOCKHOLM, Nov. 18, 2024 /PRNewswire/ -- Between November 11, 2024, and November 15, 2024, Essity Aktiebolag (publ) repurchased a total...
New Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18,...
Zero Candida Applies to List its Shares on the TSX Venture Exchange
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology...
UK Regulator MHRA Grants Nanomerics Clinical Trials Authorisation Notice for its Upcoming OC134 Clinical Trial
LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it...
Hometown NP Expands Telepsychiatry Services to 39 States Nationwide
FRANKFORT, IL / ACCESSWIRE / November 17, 2024 / Hometown NP, co-founded by Dr. Chime Ajiere, DNP, in 2023, is...
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy...